Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 8Neoplasms by Site 4Digestive System Neoplasms 4Pancreatic Neoplasms 3Neoplasms, Glandular and Epithelial 3Digestive System Diseases 3Colorectal Neoplasms 3Pancreatic Diseases 2Neoplasms by Histologic Type 2Endocrine Gland Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Thymus Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Previously Treated Metastatic Colorectal Cancer 1Pancreatic cancer, adult 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intestinal Neoplasms 1Intestinal Diseases 1

Interventions

pembrolizumab 2napabucasin 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Biological Therapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thymus Neoplasms × napabucasin × Clear all
NCT01325441 2023-11-15

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
565 enrolled 17 charts

Neoplasms, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡